Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidekazu Yamada

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
The Journal of Biological Chemistry|May 28, 2026
The iron-sulfur cluster assembly factor FDX2 is required for tumor initiation but not for growth of established tumors in transplantation modelsEifumi Hashimoto, Mai Ohuchi, Miyuki Nomura, et al.
Molecular and Clinical Oncology|March 21, 2014
Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup SurveillanceMuneaki Shimada, Ryuichiro Nishimura, Takamitsu Nogawa, et al.
Journal of Gynecologic Oncology|December 3, 2019
Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasmsWataru Yamagami, Mikio Mikami, Satoru Nagase, et al.
FEBS Letters|January 18, 2020
Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancerKei Kudo, Miyuki Nomura, Yoshimi Sakamoto, et al.
The Journal of Biological Chemistry|August 16, 2024
FDX2, an iron-sulfur cluster assembly factor, is essential to prevent cellular senescence, apoptosis or ferroptosis of ovarian cancer cellsShuko Miyahara, Mai Ohuchi, Miyuki Nomura, et al.
Gynecologic Oncology|July 21, 2007
Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancerToshio Fujimoto, Hiroshi Nanjyo, Akira Nakamura, et al.
Oncology Reports|May 24, 2008
A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit StudyYoshihito Yokoyama, Tadao Takano, Kenji Nakahara, et al.
Oncology|August 11, 2007
Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinomaJun-ichi Akahira, Hideki Tokunaga, Masafumi Toyoshima, et al.
Gynecologic Oncology Reports|September 24, 2021
Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125Takamichi Minato, Shin Ito, Bin Li, et al.
Anticancer Research|October 2, 2019
Pelvic Exenteration as Potential Cure and Symptom Relief in Advanced and Recurrent Gynaecological CancerShu Soeda, Shigenori Furukawa, Tetsu Sato, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
The Journal of Biological Chemistry|May 28, 2026
The iron-sulfur cluster assembly factor FDX2 is required for tumor initiation but not for growth of established tumors in transplantation modelsEifumi Hashimoto, Mai Ohuchi, Miyuki Nomura, et al.
Molecular and Clinical Oncology|March 21, 2014
Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup SurveillanceMuneaki Shimada, Ryuichiro Nishimura, Takamitsu Nogawa, et al.
Journal of Gynecologic Oncology|December 3, 2019
Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasmsWataru Yamagami, Mikio Mikami, Satoru Nagase, et al.
FEBS Letters|January 18, 2020
Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancerKei Kudo, Miyuki Nomura, Yoshimi Sakamoto, et al.
The Journal of Biological Chemistry|August 16, 2024
FDX2, an iron-sulfur cluster assembly factor, is essential to prevent cellular senescence, apoptosis or ferroptosis of ovarian cancer cellsShuko Miyahara, Mai Ohuchi, Miyuki Nomura, et al.
Gynecologic Oncology|July 21, 2007
Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancerToshio Fujimoto, Hiroshi Nanjyo, Akira Nakamura, et al.
Oncology Reports|May 24, 2008
A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit StudyYoshihito Yokoyama, Tadao Takano, Kenji Nakahara, et al.
Oncology|August 11, 2007
Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinomaJun-ichi Akahira, Hideki Tokunaga, Masafumi Toyoshima, et al.
Gynecologic Oncology Reports|September 24, 2021
Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125Takamichi Minato, Shin Ito, Bin Li, et al.
Anticancer Research|October 2, 2019
Pelvic Exenteration as Potential Cure and Symptom Relief in Advanced and Recurrent Gynaecological CancerShu Soeda, Shigenori Furukawa, Tetsu Sato, et al.
Pageof 5